Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder

Completed

Conditions studied: Urinary Bladder, Overactive

In brief

This study is a retrospective chart review of patients treated with BOTOX® for idiopathic Overactive Bladder (OAB) as standard of care in clinical practice. The study will determine the rate of post procedural urinary retention requiring catheterization and identify factors that may predict urinary retention.

Key facts

Study ID

NCT02557971

Run by

Allergan

People needed

315

Starts

2015-08-01

Expected to finish

2016-07-01

Last updated by the study team

2016-09-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients treated with BOTOX® for Overactive Bladder.

You may not qualify if…

• Received botulinum toxin formulations other than BOTOX® in the bladder.
• Had symptoms of OAB associated with a neurological condition.
• Had a history of chronic urinary retention treated with Clean Intermittent Catheterization (CIC) or indwelling catheter.

Where it is running

• University of California, Davis — Davis, California, United States
• Capital Region Urology — Irvine, California, United States
• The Charlotte-Mecklenburg Hospital Authority DBA Carolinas Healthcare System — Charlotte, North Carolina, United States
• Alliance Urology Specialists, PA — Greensboro, North Carolina, United States
• Forsyth Memorial Hospital Inc. dba Novant Health Urology Partners — Winston-Salem, North Carolina, United States
• MetroHealth Medical Center — Cleveland, Ohio, United States
• Virginia Women's Center Inc. — Richmond, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.